Proliferation of PTEN-deficient haematopoietic tumour cells is not affected by isoform-selective inhibition of p110β PI3-kinase and requires blockade of all class 1 PI3K activity

British Journal of Haematology

Volumn 162, Issue 2, 2013, Pages 285-289

  Stengel, Chloe ^a   Jenner, Emma ^a   Meja, Koremu ^a   Mayekar, Saloni ^a   Khwaja, Asim ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Myeloma; P110 ; PI3 kinase; PTEN; T ALL

Indexed keywords

2 (6 AMINO 9 PURINYLMETHYL) 5 METHYL 3 (2 METHYLPHENYL) 3H QUINAZOLIN 4 ONE; 5 [(2,2 DIFLUORO 1,3 BENZODIOXOL 5 YL)METHYLIDENE] 2,4 THIAZOLIDINEDIONE; 9 (1 ANILINOETHYL) 7 METHYL 2 MORPHOLINOPYRIDO[1,2 A]PYRIMIDIN 4 ONE; N (2,3 DIHYDRO 7,8 DIMETHOXYIMIDAZO[1,2 C]QUINAZOLIN 5 YL)NICOTINAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P110; UNCLASSIFIED DRUG;

CANCER CELL CULTURE; CELL PROLIFERATION; CONCENTRATION RESPONSE; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HEMATOPOIETIC TUMOR CELL; HUMAN; INTRACELLULAR SIGNALING; LETTER; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL;

MYELOMA; P110Β; PI3-KINASE; PTEN; T-ALL;

CELL PROLIFERATION; CLASS I PHOSPHATIDYLINOSITOL 3-KINASES; HEMATOLOGIC NEOPLASMS; HUMANS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; PTEN PHOSPHOHYDROLASE;

EID: 84879843662     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12353     Document Type: Letter

References (9)

1. Foster, J.G., Blunt, M.D., Carter, E. & Ward, S.G. (2012) Inhibition of PI3K signaling spurs new therapeutic opportunities in inflammatory/autoimmune diseases and hematological malignancies. Pharmacological Reviews, 64, 1027-1054.
2. Foukas, L.C., Berenjeno, I.M., Gray, A., Khwaja, A. & Vanhaesebroeck, B. (2010) Activity of any class IA PI3K isoform can sustain cell proliferation and survival. Proc Natl Acad Sci U S A, 107, 11381-11386.
3. Herman, S.E. & Johnson, A.J. (2012) Molecular pathways: targeting phosphoinositide 3-kinase p110-delta in chronic lymphocytic leukemia. Clinical Cancer Research, 18, 4013-4018.
4. Jamieson, S., Flanagan, J.U., Kolekar, S., Buchanan, C., Kendall, J.D., Lee, W.J., Rewcastle, G.W., Denny, W.A., Singh, R., Dickson, J., Baguley, B.C. & Shepherd, P.R. (2011) A drug targeting only p110alpha can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types. Biochem J, 438, 53-62.
5. Jia, S., Roberts, T.M. & Zhao, J.J. (2009) Should individual PI3 kinase isoforms be targeted in cancer? Current Opinion in Cell Biology, 21, 199-208.
6. Li, Y., Prasad, A., Jia, Y., Roy, S.G., Loison, F., Mondal, S., Kocjan, P., Silberstein, L.E., Ding, S. & Luo, H.R. (2011) Pretreatment with phosphatase and tensin homolog deleted on chromosome 10 (PTEN) inhibitor SF1670 augments the efficacy of granulocyte transfusion in a clinically relevant mouse model. Blood, 117, 6702-6713.
7. Shepherd, C., Banerjee, L., Cheung, C.W., Mansour, M.R., Jenkinson, S., Gale, R.E. & Khwaja, A. (2013) PI3K/mTOR inhibition upregulates NOTCH-MYC signalling leading to an impaired cytotoxic response. Leukemia, 27, 650-660.
8. Subramaniam, P.S., Whye, D.W., Efimenko, E., Chen, J., Tosello, V., De Keersmaecker, K., Kashishian, A., Thompson, M.A., Castillo, M., Cordon-Cardo, C., Dave, U.P., Ferrando, A., Lannutti, B.J. & Diacovo, T.G. (2012) Targeting nonclassical oncogenes for therapy in T-ALL. Cancer Cell, 21, 459-472.
9. Weigelt, B. & Downward, J. (2012) Genomic determinants of PI3K pathway inhibitor response in cancer. Front Oncol, 2, 109.